Iroko hires Novartis' Clarence Young as CMO
This article was originally published in Scrip
Philadelphia-based Iroko Pharmaceuticals, a pharma company developing specialty therapeutic products, has appointed Dr Clarence Young chief medical officer, reporting to John Vavricka, the company's president and CEO. Dr Young joins Iroko from Novartis Pharmaceuticals where he was vice-president of targeted therapies and integrated hospital care.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.